OBJECTIVE: The unique characteristics of cancer, particularly issues involving the use of
surrogate endpoints in clinical trials, present special challenges in the development of …

Much further research is required to define if, when and how best to integrate these novel
therapies, and also to define associated biomarkers that predict toxicity and select patients …

The standard treatment of advanced ovarian cancer is rapidly changing. As we begin to
understand that epithelial ovarian cancer is a heterogeneous disease, our treatment …

Objective The prognostic value of anti-angiogenesis therapy in ovarian cancer patients is
currently under debate. In this study, we assessed the effects of anti-angiogenesis therapy …

Ovarian cancer (OC) remains the most fatal disease of gynecologic malignant tumors.
Angiogenesis refers to the development of new vessels from pre-existing ones, which is …

Ovarian cancer is the leading cause of death from gynaecological malignancies in the
Western world. Despite the evolution of surgical techniques and meticulously designed …

Angiogenesis is a complex and highly regulated process that is crucial for tumor growth and
metastasis. Insights into the molecular mechanisms of tumor angiogenesis have led to the …

During the last decade we have assisted in the development of new therapeutic strategies
for the treatment of ovarian cancer, based on the best knowledge of molecular biology. One …

Epithelial ovarian cancer is the fourth biggest cause of cancer-related death in women. Over
recent decades, improvements have been made in treatment outcome in terms of response …

Ovarian cancer: beyond resistance | Nature Skip to main content Thank you for visiting
nature.com. You are using a browser version with limited support for CSS. To obtain the best …